Cited by 140Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and TreatmentsChronic Obstructive Pulmonary Disease (COPD) Research

A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice

Open access
Takemasa, Akihiro, Ishii, Yoshiki, Fukuda, Takeshi·2012·European Respiratory Journal

Abstract

Neutrophil elastase plays pivotal roles in the pathogenesis of pulmonary fibrosis. The neutrophil elastase inhibitor, sivelestat, could alleviate pulmonary fibrosis; however, the antifibrotic mechanisms have not yet been clarified. We examined the antifibrotic mechanisms, mainly focusing on a key fibrotic cytokine, transforming growth factor (TGF)-β1, in this study. To elucidate the antifibrotic mechanisms of sivelestat, we examined a murine model of bleomycin-induced early-stage pulmonary fibrosis. After intratracheal instillation of bleomycin, sivelestat was administered intraperitoneally once a day for 7 or 14 days. Bronchoalveolar lavage fluid and lung samples were examined on day 7 or day 14 after bleomycin instillation. In the bleomycin-induced early-stage pulmonary fibrosis model, the neutrophil elastase level was increased in the lungs. Sivelestat significantly inhibited the increase in lung collagen content, fibrotic changes, the numbers of total cells (including macrophages, neutrophils and lymphocytes), the levels of the active form of TGF-β1 and phospho-Smad2 in bleomycin-induced early-stage pulmonary fibrosis. The total TGF-β1 levels and relative changes of TGF-β1 mRNA expression, however, were not decreased significantly by sivelestat. These results suggest that sivelestat alleviated bleomycin-induced pulmonary fibrosis via inhibition of both TGF-β activation and inflammatory cell recruitment in the lung.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00127011

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacological inhibition of neutrophil elastase by sivelestat protects mice from bleomycin induced lung fibrosis, demonstrating that at least in lungs, neutrophil elastase is pro-fibrotic.

    “Furthermore, pharmacological inhibition of neutrophil elastase by sivelestat protects mice from bleomycin induced lung fibrosis (167), demonstrating that at least in lungs, neutrophil elastase is pro-fibrotic.”

    From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [167]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Denholm EM, Rollins SM. Expression and secretion of transform- ing growth factor-b by bleomycin-stimulated rat alveolar macro- phages. Am J Physiol 1993; 264: L36-L42.

Cited by

Sorted by citations

Authors
Takemasa, A., Ishii, Y., & Fukuda, T.
Affiliations
  • Dokkyo Medical University (JP)
  • Dokkyo University (JP)
Venue
European Respiratory Journal
Published
2012-03-22
Volume
40
Issue
6
Pages
1475-1482
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2137335759
Cited by
140
References
28
Citations by year
2026: 9 · 2025: 13 · 2024: 13 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 11 · 2019: 11 · 2018: 11 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 8 · 2013: 3 · 2012: 3
FWCI
5.41
Type
journal article
Language
en
Open access
Locations
  • European Respiratory Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
neutrophil elastase, sivelestat, pulmonary fibrosis, bleomycin-induced lung injury, TGF-β1 activation, Smad2 phosphorylation, lung inflammation, antifibrotic mechanism, collagen deposition, neutrophil elastase inhibitor
MeSH terms
Animals, Bleomycin, Collagen, Fibrosis, Glycine, Inflammation, Lung, Male, Mice, Inbred C57BL, Phosphorylation, Pulmonary Fibrosis, Sulfonamides, Time Factors, Serine Proteinase Inhibitors, Bronchoalveolar Lavage, Leukocyte Elastase, Mice, Smad2 Protein, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review